Stimcell Energetics Inc. issued 250,000 shares of common stock to Stonegate.
“On March 19, 2026, the Company issued 250,000 shares of its common stock to Stonegate as consideration for the services provided under the Advisory Services Agreement”
Stimcell Energetics Inc. — fact timeline
Source-grounded facts extracted from Stimcell Energetics Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Stimcell Energetics Inc. entered into Advisory Services Agreement with Stonegate Capital Partners, Inc. valued at 250,000 shares of its common stock (effective 2026-03-12).
“On March 12, 2026, StimCell Energetics Inc. (the “Company”) entered into an Advisory Services Agreement (the “Agreement”) with Stonegate Capital Partners, Inc. ("Stonegate") to provide research coverage and institutional investor outreach services.”
Stimcell Energetics Inc.: Company completed a 1-for-15 reverse stock split and decreased authorized capital from 7,500,000,000 to 500,000,000 shares via amendment to articles of incorporation (effective 2024-11-01).
“1:15 Reverse Stock Split Effective November 1, 2024, Cell MedX Corp. (the “Company”) completed a 1-for-15 reverse split (the “Reverse Split”) of its common stock. As a result of the Reverse Split, the Company’s authorized capital was decreased from 7,500,000,000 shares common stock, par value $0.001, of which 297,236,373 shares of common stock were outstanding immediately prior to the Reverse Split, to 500,000,000 shares of common stock, par value $0.001, of which approximately 19,815,758 are outstanding, subject to adjustment for fractional interests resulting from the Reverse Split.”
Stimcell Energetics Inc.: Company amended its articles of incorporation to change name from Cell MedX Corp. to Stimcell Energetics Inc (effective 2024-11-01).
“Concurrent with the Reverse Split, the Company amended its articles of incorporation to change the Company’s name from “Cell MedX Corp.” to “Stimcell Energetics Inc.” (the “Name Change”)”
Stimcell Energetics Inc.: Increase in authorized capital from 300,000,000 to 7,500,000,000 shares of common stock (effective 2024-04-01).
“On April 1, 2024, Cell MedX Corp. (the “Company”), amended its articles of incorporation to increase the authorized capital of the Company from 300,000,000 shares of common stock, par value $0.001 (the “Common Stock”) to 7,500,000,000 shares of Common Stock (the “Increase in Authorized Capital”).”
Stimcell Energetics Inc. entered into Private Placement Subscription Agreement with Amir Vahabzadeh valued at 30,000 USD (effective 2024-03-12).
“On March 12, 2024, Amir Vahabzadeh, a director of Cell MedX Corp. (the "Company"), together with his spouse, subscribed for 1,000,000 units (each a "Unit") of the Company at a price of US$0.03 per Unit for total $30,000 in a private placement offering (the "Offering").”
Brad Hargreaves resigned as Director at Stimcell Energetics Inc..
“On February 27, 2024, Mr. Brad Hargreaves resigned from the Board of Directors of Cell MedX Corp. (the “Company”).”
Amir Vahabzadeh was appointed as Director at Stimcell Energetics Inc..
“the Company's board of directors was increased to seven (7) directors by the appointment of Mr. Jeffs and Mr. Amir Vahabzadeh as directors”
David Jeffs was appointed as Director at Stimcell Energetics Inc..
“the Company's board of directors was increased to seven (7) directors by the appointment of Mr. Jeffs and Mr. Amir Vahabzadeh as directors”
David Jeffs was appointed as Chief Executive Officer at Stimcell Energetics Inc..
“On December 12, 2023, Mr. David Jeffs was appointed as Chief Executive Officer of the Company”
Brad Hargreaves resigned as Vice President of Technology and Operations at Stimcell Energetics Inc..
“Mr. Brad Hargreaves resigned as Vice President of Technology and Operations of the Company”
Dwayne Yaretz resigned as Chief Executive Officer at Stimcell Energetics Inc..
“On December 12, 2023, Mr. Dwayne Yaretz resigned as Chief Executive Officer of the Company”
Joao da Costa resigned as Chief Operating Officer at Stimcell Energetics Inc..
“On November 7, 2023, Mr. Joao da Costa resigned as Chief Operating Officer of Cell MedX Corp.”
Mr. McEnulty departed as Director at Stimcell Energetics Inc..
“who resigned from his position as CEO of the Company on April 25, 2022. Mr. McEnulty will continue to serve on the Company’s board of directors.”
Dwayne Yaretz was appointed as Chief Executive Officer at Stimcell Energetics Inc..
“Mr. Yaretz was appointed Chief Executive Officer of the Company, replacing Mr. McEnulty, who resigned from his position as CEO.”
Dwayne Yaretz was appointed as Director at Stimcell Energetics Inc..
“to appoint Mr. Dwayne Yaretz as a director to fill the vacancy created by the increase in the number of directors.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.